Papers with UM affiliation (24)

  1. Shi C, Yang EJ, Liu Y, Mou PK, Ren G, Shim JS*. Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression. Oncogene, Accepted.
  2. Hwang HY, Shim JS, Kim D, Kwon HJ. Antidepressant Drug Sertraline Modulates AMPK-MTOR Signaling-Mediated Autophagy via Targeting Mitochondrial VDAC1 Protein. Autophagy, 2020; DOI: 10.1080/15548627.2020.1841953
  3. Lyu J, Yang EJ, Zhang B, Wu C, Pardeshi L, Shi C, Mou PK, Liu Y, Tan K, Shim JS*. Synthetic lethality of RB1 and aurora A is driven by stathmin-mediated disruption of microtubule dynamics. Nat Commun, 2020; 11(1):5105.
  4. Liu Y, Yang EJ, Shi C, Mou PK, Zhang B, Wu C, Lyu J, Shim JS*. Histone acetyltransferase (HAT) p300/CBP inhibitors induce synthetic lethality in PTEN-deficient colorectal cancer cells through destabilizing AKT. Int J Biol Sci, 2020; 16(11):1774-1784.
  5. Zhang B, Lyu J, Yang EJ, Liu Y, Wu C, Pardeshi L, Tan K, Chen Q, Xu X, Deng CX, Shim JS*. Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells. Acta Pharm Sin B, 2020; 10(4):615-627.
  6. Lyu J, Yang EJ, Shim JS*. Cholesterol trafficking: an emerging therapeutic target for angiogenesis and cancer. Cells, 2019; 8(5), pii: E389.
  7. Wu C, Lyu J, Yang EJ, Liu Y, Zhang B, Shim JS*. Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells. Nat Commun, 2018; 9(1):3212.
  8. Liu Y, Yang EJ, Zhang B, Miao Z, Wu C, Lyu J, Tan K, Wong KH, Poon TCW, Shim JS*. PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora A kinases. Cancer Lett, 2018; 436:28-37.
  9. Zhang B, Lyu J, Liu Y, Wu C, Yang EJ, Pardeshi L, Tan K, Wong KH, Chen Q, Xu X, Deng CX, Shim JS*. BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition. Oncogene, 2018; 37(49):6341-6356.
  10. Lyu J, Yang EJ, Head SA, Ai N, Zhang B, Wu C, Li RJ, Liu Y, Chakravarty H, Zhang S, Tam KY, Dang Y, Kwon HJ, Ge W, Liu JO, Shim JS*. Astemizole inhibits mTOR signaling and angiogenesis by blocking cholesterol trafficking. Int J Biol Sci, 2018; 14(10):1175-1185.
  11. Lyu J, Yang EJ, Head SA, Ai N, Zhang B, Wu C, Li RJ, Liu Y, Yang C, Dang Y, Kwon HJ, Ge W, Liu JO, Shim JS*. Pharmacological blockade of cholesterol trafficking by cepharanthine in endothelial cells suppresses angiogenesis and tumor growth. Cancer Lett, 2017; 409:91-103.
  12. Head SA, Shi WQ, Yang EJ, Nacev BA, Hong SY, Pasunooti KK, Li RJ, Shim JS, Liu JO. Simultaneous targeting of NPC1 and VDAC1 by itraconazole leads to synergistic inhibition of mTOR signaling and angiogenesis. ACS Chem Biol, 2017; 12(1):174-182.
  13. Cho YS, Yen CN, Shim JS, Kang DH, Kang SW, Liu JO, Kwon HJ. Antidepressant indatraline induces autophagy and inhibits restenosis via suppression of mTOR/S6 kinase signaling pathway. Sci Rep, 2016; 6:34655.
  14. Du B and Shim JS*. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules, 2016; 21(7):E965.
  15. Yang EJ, Wu C, Liu Y, Lv J, Shim JS*. Revisiting non-cancer drugs for cancer therapy. Curr Top Med Chem, 2016; 16(19):2144-55.
  16. Shim JS, Li RJ, Bumpus NN, Head SA, Kumar K, Yang EJ, Lv J, Shi W, Liu JO. Divergence of anti-angiogenic activity and hepatotoxicity of different stereoisomers of itraconazole. Clin Cancer Res, 2016; 22(11):2709-20.
  17. Head SA, Shi WQ, Zhao L, Gorshkov K, Pasunooti KK, Chen Y, Deng Z, Li RJ, Shim JS, Tan W, Hartung T, Zhang J, Zhao Y, Colombini M, Liu JO. The antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells. Proc Natl Acad Sci USA, 2015; 112(52):E7276-85.
  18. Wang G, Rajpurohit SK, Delaspre F, Walker SL, White DT, Ceasrine A, Kuruvilla R, Li RJ, Shim JS, Liu JO, Parsons MJ, Mumm JS. First quantitative high-throughput screen in zebrafish identifies novel pathways for increasing pancreatic β-cell mass. eLife, 2015; 10.7554/eLife.08261.
  19. Lv J and Shim JS*. Existing drugs and their application in drug discovery targeting cancer stem cells. Arch Pharm Res, 2015; 38(9):1617-26.
  20. Kim NH, Pham NB, Quinn RJ, Shim JS, Cho H, Cho SM, Park SW, Kim JH, Seok SH, Oh JW, Kwon HJ. The small molecule R-(-)-β-O-methylsynephrine binds to nucleoporin 153 kDa and inhibits angiogenesis. Int J Biol Sci, 2015; 11(9):1088-99.
  21. Shim JS*, Li RJ, Lv J, Head SA, Yang EJ, Liu JO*. Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism. Cancer Lett, 2015; 362(1):106-15.
  22. Wang M1, Shim JS1, Li RJ1, Dang Y, He Q, Das M, Liu JO. Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways and an inhibitor of prostate cancer. Br J Pharmacol, 2014; 171(19):4478-89.
  23. Park H1, Shim JS1, Kim BS, Jung HJ, Huh TL, Kwon HJ. Purpurin inhibits adipocyte-derived leucine aminopeptidase and angiogenesis in a zebrafish model. Biochem Biophys Res Comm, 2014; 450(1):561-7.
  24. Shim JS* and Liu JO*. Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci, 2014; 10(7):654-63.

Papers with Non-UM affiliation (40)

  1. He R, Yu ZH, Zhang RY, Wu L, Gunawan AM, Lane BS, Shim JS, Zeng LF, He Y, Chen L, Wells CD, Liu JO, Zhang ZY. Exploring the existing drug space for novel pTyr mimetic and SHP2 inhibitors. ACS Med Chem Lett, 2015; 6(7):782-6.
  2. Wissing MD, Dadon T, Kim E, Piontek KB, Shim JS, Kaelber NS, Liu JO, Kachhap SK, Nelkin BD. Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression. Oncol Rep, 2014; 32(1):419-24.
  3. Zhang F, Bhat S, Gabelli SB, Chen X, Miller MS, Nacev BA, Cheng YL, Meyers DJ, Tenney K, Shim JS, Crews P, Amzel LM, Ma D, Liu JO. Pyridinylquinazolines selectively inhibit human methionine aminopeptidase-1 in cells. J Med Chem, 2013; 56(10):3996-4016.
  4. Wissing MD, Mendonca J, Kim E, Kim E, Shim JS, Kaelber NS, Kant H, Hammers H, Commes T, Van Diest PJ, Liu JO, Kachhap SK. Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cells. Cancer Biol Ther, 2013; 14(5):401-10.
  5. Choi SM, Kim Y, Shim JS, Park JT, Wang RH, Leach SD, Liu JO, Deng CX, Ye Z, Jang YY. Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology, 2013; 57(6):2458-68.
  6. Bhat S, Shim JS, Liu JO. Tricyclic thiazoles are a new class of angiogenesis inhibitors. Bioorg Med Chem Lett, 2013; 23(9):2733-7.
  7. Kamiyama H, Rauenzahn S, Shim JS, Karikari CA, Feldmann G, Hua L, Kamiyama M, Schuler FW, Lin MT, Beaty RM, Karanam B, Liang H, Mullendore ME, Mo G, Hidalgo M, Jaffee E, Hruban RH, Jinnah HA, Roden RB, Jimeno A, Liu JO, Maitra A, Eshleman JR. Personalized chemotherapy profiling using cancer cell lines from selectable mice. Clin Cancer Res, 2013; 19(5):1139-46.
  8. Shim JS, Rao R, Beebe K, Neckers L, Han I, Nahta R and Liu JO. Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. J Natl Cancer Inst, 2012; 104(20):1576-90.
  9. Bhat S, Shim JS, Zhang F, Chong CR and Liu JO. Substituted oxines inhibit endothelial cell proliferation and angiogenesis. Org Biomol Chem, 2012; 10(15):2979-2992.
  10. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO and Pan D. Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAP. Gene Dev, 2012; 26(12): 1300-1305.
  11. Rovira M, Huang W, Yusuff S, Shim JS, Ferrante AA, Liu JO and Parsons MJ. Chemical screen identifies FDA-approved drugs and target pathways that induce precocious pancreatic endocrine differentiation. Proc Natl Acad Sci USA, 2011; 108(48): 19264-19269.
  12. Platz EA, Yegnasubramanian S, Liu JO, Chong CR, Shim JS, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E and Nelson WG. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov, 2011; 1(1): 68-77, Inaugural Issue.
  13. Lin J, Haffner MC, Zhang Y, Lee BH, Brennen WN, Britton J, Kachhap SK, Shim JS, Liu JO, Nelson WG, Yegnasubramanian S and Carducci MA. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate, 2011; 71(4): 333-343.
  14. Shim JS, Matsui Y, Bhat S, Nacev BA, Xu J, Bhang HE, Dhara S, Han KC, Chong CR, Pomper MG, So A and Liu JO. Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J Natl Cancer Inst, 2010; 102(24): 1855-1873.
  15. Jung HJ, Kim JH, Shim JS and Kwon HJ. A novel Ca2+/calmodulin antagonist HBC inhibits angiogenesis and down-regulates hypoxia-inducible factor. J Biol Chem, 2010; 285(33): 25867-25874.
  16. Jung HJ1, Shim JS1, Lee J, Song YM, Park KC, Choi SH, Kim ND, Yoon JH, Mungai PT, Schumacker PT and Kwon HJ. Terpestacin inhibits tumor angiogenesis by targeting UQCRB of mitochondrial complex III and suppressing hypoxia-induced ROS production and cellular oxygen sensing. J Biol Chem, 2010; 285(15): 11584-11595.
  17. Jung HJ, Shim JS, Park J, Ha HJ, Kim JH, Kim JG, Kim ND, Yoon JH and Kwon HJ. Identification and validation of calmodulin as a binding protein of an anti-proliferative small molecule 3,4-dihydroisoquinolinium salt. Proteom Clin Appl, 2009; 3(4): 423-432.
  18. Shim JS, Park HM, Lee J and Kwon HJ. Global and focused transcriptional profiling of small molecule aminopeptidase N inhibitor reveals its mechanism of angiogenesis inhibition. Biochem Biophys Res Comm, 2008; 371(1): 99-103.
  19. Jung HJ, Shim JS, Suh YG, Kim YM, Ono M and Kwon HJ. Potent inhibition of in vivo angiogenesis and tumor growth by a novel cyclooxygenase-2 inhibitor, enoic acanthoic acid. Cancer Sci, 2007; 98(12): 1943-1948.
  20. Yang E1, Shim JS1, Woo HJ, Kim KW and Kwon HJ. Aminopeptidase N/CD13 induces angiogenesis through interaction with a pro-angiogenic protein, galectin-3. Biochem Biophys Res Comm, 2007; 363(2): 336-341.
  21. Shim JS, Lee J, Kim KN and Kwon HJ. Development of a new Ca2+/calmodulin antagonist and its anti-proliferative activity against colorectal cancer cells. Biochem Biophys Res Comm, 2007; 359(3): 747-751.
  22. Choi HS, Shim JS, Kim JA, Kang SW and Kwon HJ. Discovery of gliotoxin as a new small molecule targeting thioredoxin redox system. Biochem Biophys Res Comm, 2007; 359(3): 523-528.
  23. Jung HJ, Shim JS, Lee HB, Kim CJ, Kuwano T, Ono M and Kwon HJ. Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo. Biochem Biophys Res Comm, 2007; 353(2): 376-380.
  24. Kim DH, Shim JS, and Kwon HJ. Coordinated transcriptional regulation of calmegin, a testis-specific molecular chaperon, by histone deacetylase and CpG methyltransferase. Exp Mol Med, 2005; 37(5): 492-496.
  25. Shim JS, Lee HK, Park HM, Kim JO, Kim EK, Hwang KH, Kim KT, Park SH, Lee JH, and Kwon HJ. Development of an angiogenesis-focused cDNA chip and validation of its functionality. Exp Mol Med, 2005; 37(4): 365-370.
  26. Hur JM, Shim JS, Jung HJ, and Kwon HJ. Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro. Exp Mol Med, 2005; 37(2): 133-137.
  27. Lee J1, Shim JS1, Jung SA, Lee ST, and Kwon HJ. N-Hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity. Bioorg Med Chem Lett, 2005; 15(1): 181-183.
  28. Shim JS and Kwon HJ. Chemical genetics for therapeutic target mining. Expert Opin Ther Targets, 2004; 8(6): 653-661. (Review).
  29. Kim SJ, Bang EK, Kwon HJ, Shim JS, and Kim BH. Modified oligonucleotides containing lithocholic acid in their backbones: their enhanced cellular uptake and their mimicking of hairpin structures. Chembiochem, 2004; 5(11): 1517-1522.
  30. Shim JS, Lee J, Park HJ, Park SJ, and Kwon HJ. A new curcumin derivative, HBC, interferes with the cell cycle progression of colon cancer cells via antagonization of the Ca2+/calmodulin function. Chem Biol, 2004; 11: 1455-1463.
  31. Kim SN, Kim WG, Jung HJ, Shim JS, Kim HJ, Lee HB, Han JT, Kim CJ, Baek NI, Yoo ID and Kwon HJ. Cell cycle inhibitory activity of 4-hydroxy-3-(3′-methyl-2′-butenyl)- benzoic acid from Curvularia sp. KF119. J Antibiotics, 2004; 57(9): 605-608.
  32. Shim JS, Kim DH, and Kwon HJ. Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells. Oncogene, 2004; 23(9): 1704-1711.
  33. Shim JS, Lee HS, Shin J, and Kwon HJ. Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro. Cancer Lett, 2004; 203(2):163-169.
  34. Shim JS, Kim JH, Lee J, Kim SN, and Kwon HJ. Anti-angiogenic activity of the homoisoflavanone from Cremastra appendiculata. Planta Medica, 2004; 70(2): 171-173.
  35. Shim JS, Kim JH, Cho HY, Yum YN, Kim SH, Park HJ, Shim BS, Choi SH, and Kwon HJ. Irreversible inhibition of CD13/aminopeptidase N by the anti-angiogenic agent curcumin. Chem Biol, 2003; 10: 695-704.
  36. Kim JH1, Shim JS1, Lee SK, Kim KW, Rha SY, Chung HC and Kwon HJ. Microarray-based analysis of anti-angiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: crucial Involvement of the down-regulation of matrix metalloproteinase. Cancer Sci (formerly Jpn J Cancer Res), 2002; 93(12): 1378-1385.
  37. Kwon HJ, Kim DH, Shim JS and Ahn JW. Apicularen A, a macrolide from Chondromyces sp., inhibits growth factor induced in vitro angiogenesis. J Microbiol Biotechn, 2002; 12(4): 702-705.
  38. Shim JS, Kim DH, Jung HJ, Kim JH, Lim D, Lee SK, Kim KW, Ahn JW, Yoo JS, Rho JR, Shin J and Kwon HJ. Hydrazinocurcumin, a novel synthetic curcumin derivative, is a potent inhibitor of endothelial cell proliferation. Bioorg Med Chem, 2002; 10: 2987-2992.
  39. Kwon HJ, Shim JS, Kim JH, Cho HY, Yum YN, Kim SH and Yu J. Betulinic acid inhibits growth factor-induced in vitro angiogenesis via the modulation of mitochondrial function in endothelial cells. Cancer Sci (formerly Jpn J Cancer Res), 2002; 93: 417-425.
  40. Shim JS, Lee HJ, Park SS, Cha BG and Chang HR. Curcumin-induced apoptosis of A-431 cells involves caspase-3 activation. BMB Rep (formerly J Biochem Mol Biol), 2001; 34(3): 189-193.